SignalXSignalX

VERA Vera Therapeutics, Inc.

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Vera Therapeutics, Inc. Overview

Vera Therapeutics, Inc. (VERA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • No newly added risk factor this quarter; risks consistent with prior 10-K filing
  • • Material update on financing: $497.4M cash and marketable securities as of Sept 30, 2025, sufficient to fund operations beyond 12 months but capital needs remain high
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$80M

ROE

-20.1%

Total Assets

$518M

Source: XBRL data from Vera Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Vera Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.